Exclusive Patent License for PEDF Peptides and Retinal Degeneration Treatment

Wed, 01 Apr 2026 09:47:08 +0000
Healthcare

The National Eye Institute, part of the NIH, has published a notice of its intent to grant an Exclusive Patent License to Perpetual Biosciences, Inc. (New York, NY) covering PEDF (Pigment Epithelium-Derived Factor) peptides for treating retinal degeneration. The license would cover multiple patent applications and issued patents across US, Australia, Canada, European, and Japanese jurisdictions. The public comment period closes on April 16, 2026.